如何评价干扰素与核苷和核苷酸类药物的联合治疗  

How to evaluate combination therapy using interferon and nucleos(t) ide analogues

作　　者：陈璐[1] 谢青[1] 

机构地区：[1]上海交通大学医学院附属瑞金医院感染科,上海200025

出　　处：《临床肝胆病杂志》2016年第11期2050-2053,共4页Journal of Clinical Hepatology

摘　　要：慢性乙型肝炎目前仍然是影响我国人民健康的重要疾病,主要原因是与其相关的肝硬化和肝细胞癌。目前治疗慢性乙型肝炎的药物主要有干扰素与核苷和核苷酸类药物,2种方法都各自存在着优缺点,进一步寻找和探索联合治疗是目前慢性乙型肝炎治疗的重要方向。分析了各类联合治疗的进展,针对目前联合治疗方法及患者的选择提出了意见。Chronic hepatitis B is still one of the most important chronic diseases in China because of its high relevance to liver cirrhosis and hepatic cell cancer（ HCC）. Currently,interferon and nucleos（ t） ide analogues are two main treatments for chronic hepatitis B,but they have advantages and disadvantages. More investigations are needed to explore better ways for treating this disease,and combination therapy might be one of the options. This article analyzes the advances in various combination therapies and points out views about the selection of combination therapies and patients.

关 键 词：肝炎 乙型 慢性 干扰素类 核苷类 核苷酸类 药物疗法 联合 

分 类 号：R512.62[医药卫生—内科学]